Related Experiment Video
Updated: Nov 12, 2025
08:50
Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
Published on: October 18, 2024
814
Pediatric Metabolic and Bariatric Surgery.
Adi Steinhart1, Deborah Tsao2, Janey S A Pratt3
1Department of Pediatrics, Stanford University School of Medicine, 1017 Paradise Way, Palo Alto, CA 94306, USA.
The Surgical Clinics of North America
|March 21, 2021
Summary
Severe childhood obesity requires early intervention, including metabolic and bariatric surgery, to improve long-term health and survival. Lifestyle changes alone are insufficient for treating this complex condition.
Area of Science:
- Pediatric Endocrinology
- Public Health
- Genetics
Background:
- Childhood obesity is a serious health issue linked to reduced quality of life and premature death.
- Obesity has a polygenic etiology, and recognizing this can reduce implicit bias in treatment.
- Current treatments often fail to adequately address severe pediatric obesity.
Purpose of the Study:
- To highlight the inadequacy of current treatments for severe childhood obesity.
- To advocate for early referral to multidisciplinary centers for severe pediatric obesity.
- To emphasize the benefits of timely intervention on quality and quantity of life.
Main Methods:
- Review of current guidelines for severe childhood obesity treatment.
- Analysis of the etiological factors contributing to childhood obesity.
- Evaluation of the effectiveness of various treatment modalities.
Main Results:
- Severe childhood obesity significantly decreases health-related quality of life and increases mortality risk.
- Metabolic and bariatric surgery is recommended for severe obesity at any age when BMI exceeds 120% of the 95th percentile.
- Medications and lifestyle counseling are insufficient for severe cases.
Conclusions:
- Early referral to specialized multidisciplinary treatment centers is crucial for managing severe childhood obesity.
- Timely intervention, including surgical options, can substantially improve both the quality and duration of life for affected children.
- Recognizing obesity as a complex, polygenic disease is essential for effective and unbiased care.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
80
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
80
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
85
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
85
01:26Kidney Transplant II: Surgical Procedure
136
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
136
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
84
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
84
01:15Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
436
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
436
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
69
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
69